INTRODUCTION
The efficacy of pharmacological therapies and psychotherapy in the treatment of depression and anxiety disorders has been proven 1 . Even though there is a large number of patients all over the world and a high prevalence of these diseases [2] [3] [4] , the most common first and second line treatment methods are antidepressant drugs for a number of reasons such as lack of personnel skilled in providing psychotherapy, economic reasons and limitations of time and space. The use of antidepressants has increased dramatically in many western countries in the last 20 years 1 . In particular, selective serotonin reuptake inhibitors (SSRI) and the newgeneration antidepressants are being prescribed i n t e n s i v e l y 5 . T h e s a l e s o f t r i c y c l i c antidepressants (TCAs) have been reduced while sales of SSRIs have increased in the last twenty years in the Nordic countries 6 . However, TCAs are still being used extensively worldwide 7 . SSRI agents are generally better tolerated than TCAs and both groups are thought to have nearly the same level of activity 8 . Treatment non-compliance is defined as patients not fulfilling the treatment program as r e c o m m e n d e d b y t h e i r p h y s i c i a n . Noncompliance leads to negative consequences such as the emergence of new episodes, prolongation of treatment, higher hospitalization rates, loss of labor and increased cost [9] [10] [11] . Metaanalyses have shown that the rate of noncompliance varied between 21-60% for SSRIs and TCAs 9, 12, 13 . Of patients starting therapy with an antidepressant, 30-83% discontinue the treatment without consulting a physician because of many factors such as physician-patient communication, family support, clinical response to treatment and side effects [14] [15] [16] . Side effects associated with the use of medications have been found to be responsible for approximately 30% of all noncompliance cases 12, 13 . In one study, it was found that at least half of the patients, who had been using SSRIs were found to have side-effects, which may cause problems 16 . In this study, we aimed to identify side effects that cause noncompliance and also to find out the differences between two groups using either SSRIs or TCAs in an outpatients population.
METHODS

Selection and Description of Cases
A total of 264 patients (134 men, 130 women) who were admitted to GMMF Department of Psychiatry between the years 2004-2005, whose antidepressant treatment was initiated for treatment of depression (n=108), anxiety (n=135), or somatization (n=21) but who quit treatment without consent of a physician or any control were included in the study. Before leaving treatment 166 of these cases were using SSRIs and 98 were using TCAs.
A demographic data form was completed during face to face interviews with the patients. Sociodemographic characteristics of cases, medications and treatment protocols were assessed with a semi-structured questionnaire which included the reasons for non-compliance and how long the patient stayed on the prescribed treatment. Medications were evaluated in two main groups (TCAs and SSRIs) s and sub-groups were defined according to the patients' diagnoses. In order to identify the effect of medication-related side effects, causes for discontinuation were classified as "adverse events" and others". No stand alone evaluation was made based on the active ingredients of the medications and the dosage.
Exclusion Criteria
Patients with non-mental chronic medical diseases (paraplegia, osteoarthritis, heart failure, etc.) that may affect social functioning, dementia, mental retardation, epilepsy, neurological diseases that could cause organic brain disorder such as head trauma, substance abuse other than smoking and pregnant women were excluded from the study.
Statistics
Analyzes were performed with SPSS 15.0 software. Frequency, percentage, mean and standard deviation were taken as descriptive statistics. After studying the data for normal distribution with the Kolmogorov-Smirnov test, the Student t test was used for continuous variables, which were found to comply with a normal distribution and the Mann-Whitney U test was used for data that did not conform to the normal distribution criteria. The Chi-Square test was used to compare discrete variables. For statistical significance, p<0.05 was adopted.
RESULTS
It was found that 194 of patients (73.2%) had treatment non-compliance due to a variety of reasons such as inadequate effect of medication, patient or disease characteristics and doctorpatient relationship and 71 (26.8%) had noncompliance due to side effects. Twenty out of 98 patients (20.4%) in the TCA group and 51 among 166 patients (30.7%) in the SSRI group quit the treatment due to side effects of the drug. No difference was found in terms of discontinuation rates due to adverse events between the two groups ( χ 2 =3.23, p=0.07).
Comparison of the sociodemographic and clinical aspects of patients who discontinued treatment due to adverse effects in both groups is given in Table 1 . No difference was found in terms of age, educational level and gender between groups. When patients who discontinued treatment due to side effects or other reasons were compared within and between the two groups, the rate of discontinuation due to side effects was found to be higher than the rate of discontinuation due to other causes in patients with the diagnosis of somatization disorder in the TCA group (p=0.013). Figure 1 shows side effects of medications that caused discontinuation in the SSRI and TCA groups. Side effects that caused non-compliance were found to be weight gain (7.5%), anxiety (4.9%), sexual problems (4.9%), dizziness (4.9%), insomnia (3.0%), nausea (3.0%), sedation (2.6%), pruritus (2.3%), increased appetite (1.1%) and constipation (1.1%). TCAs caused sedation, constipation, and palpitations and SSRIs caused insomnia, anxiety and nausea at significantly higher rates (p<0.05).
No difference was detected in terms of duration of treatment between groups (p=0.842). In addition, percentages of individual side effects showed no difference in the first 3 months and after 3 months in the group that discontinued treatment due to side effects associated with the use of medications (Figure 2 ). 
DISCUSSION
The aim of this study was to determine the side e f f e c t s , w h i c h d i s r u p t c o m p l i a n c e t o antidepressant treatment and to compare the SSRI and TCA groups. In this study, it was found that treatment compliance was impaired in 26.8% of patients due to side effects. The discontinuation rate due to side effects was similar to some previous studies (16) . In a study evaluating 401 patients it was found to be 36%. No difference was found in terms of age, educational level and gender between the subgroup of drop-outs due to side effects and the subgroup of drop-outs due to other reasons.
In our study, side effects that caused noncompliance were found to be weight gain (7.5%), anxiety (4.9%), sexual problems (4.9%), dizziness (4.9%), insomnia (3.0%), nausea (3.0%), sedation (2.6%), pruritus (2.3%), increased appetite (1.1%) and constipation (1.1%). TCAs caused sedation, constipation, and palpitation and SSRIs caused insomnia, anxiety and nausea at significantly higher rates. These side effects of TCAs, which occured more often than placebo and SSRIs, were also found in previous studies 17 . Sedation, orthostatic hypotension and anticholinergic side effects have been reported to be higher with TCAs than SSRIs in many studies 18, 19 . These side effects are related to receptor interaction profiles of antidepressants and they may also differ within the drug groups 19 . In a meta-analysis of 11 studies with a total of 601 patients, dry mouth, constipation, diarrhea, drowsiness, lethargy, dizziness, anorexia, tremor and sweating were more common with TCAs while nausea/vomiting and sleep disorders were reported more frequently with SSRIs. This study indicates the difference in the side effect profile between the two groups. In this study, the TCAs were associated with a higher rate of medication drop-out 20 . The side effects of SSRIs that were found to be more frequent in our study (insomnia, anxiety, and nausea) have been highlighted in previous studies. In general, gastrointestinal problems, headache, sedation, insomnia, activation, parethesis and sexual side effects are often reported in the acute period of SSRI treatment 18 . The point to be considered here is, although many studies have reported rates of adverse events, in our study, only the rates of discontinuation due to side effects was stated.
In our study, the most common side effect that caused non-compliance was weight gain (7.5%). Previous studies have emphasized that risks of weight gain associated with the use of medications are different. Relative risks of antidepressants in terms of weight gain may have large differences within the same drug group. In general, SSRIs also cause sexual dysfunction and weight gain more commonly, when compared with atypical antidepressants (eg, bupropion and nefazodone) 18 . Rates of sexual side effects have been reported to be between 25-50% in many studies. In our study, withdrawal rate due to these adverse events was found to be 4.9%. This may be related to development of tolerance to many side effects over time or the difference in short-and long-term consequences of adverse effects. Weight gain and sexual side effects have been reported to have an increasing importance, especially during the maintenance period 21 . The American Psychiatric Association (APA) recommends to maintain acute treatment of depression for 6 to 8 weeks and to continue treatment for 4-9 months after the symptoms have resolved in order to ensure complete remission and to avoid relapses 22 . However, many patients leave treatment early (before 3 months). Discontinuation rates in the first 3 months can increase up to 70% depending on the prescribed antidepressant and the patient population 16 . Leaving treatment is largely seen in the first month. In one study, 28% of patients left treatment within the first month and 44% within the first 3 months 22 . In our study, the highest rate of discontinuation due to adverse events was recorded within the first month.
This finding is also consistent with previous studies. In a study with patients in primary care, who had been prescribed tricyclic antidepressants, 21% of the patients dropped-out within the first 2 weeks of treatment and 10% of the rest droppedout in each subsequent two-week period; as a result, only half of them were on treatment after 4 months 23 . In a study of a large sample, discontinuation due to adverse events was found to be significantly higher in patients using highdose TCA than users of low-dose 7 . When studies are evaluated as a whole, it is a common consideration that, in addition to the patient's justification, cessation of treatment in the early period of treatment (before 3 months) is also related to side-effects.
As a result, although the two groups had different side effect profiles and showed no significant difference in terms of the consequences of side effects on treatment, discontinuation is an important finding. Collection of data non-specific to individual drug substance and dose is a limitation of our study. Although we detected a significant difference related to somatization disorder, studying this difference in a more homogeneous and wide group would be advisable.
In the future, it would be useful to conduct larger studies evaluating drug doses, drugs in each group and diagnostic groups separately. It may be useful to switch medications and inform patients to prevent non-compliance.
